Enasidenib Mesylate Clinical Trials
2 recruitingDrug
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
Acute Myeloid Leukemia
City of Hope Medical Center35 enrolled2 locationsNCT03728335
Recruiting
Phase 2
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia+4 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT03683433